Top 5 Heart Failure Apps for Primary Care Providers &amp; Patients

March 25th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.

August 30th 2023

Marijuana Use Tied to Increased Risk for Myocardial Infarction in People Aged 50 Years and Younger

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

March 24th 2025

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.

Patient Care Editorial Staff

October 29th 2020

First Rivaroxaban Generics (2.5 mg) Get FDA Approval

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Grace Halsey

March 5th 2025

FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

February 28th 2025

Maternal Mortality Due to Cardiovascular Disease More Than Doubles in the US

The Loss of Pulse Detection feature will begin rolling out in the US late next month.

Related Content

March 25th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.

August 30th 2023

Marijuana Use Tied to Increased Risk for Myocardial Infarction in People Aged 50 Years and Younger

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

March 24th 2025

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.

Patient Care Editorial Staff

October 29th 2020

First Rivaroxaban Generics (2.5 mg) Get FDA Approval

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Grace Halsey

March 5th 2025

FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

February 28th 2025